(Bloomberg) — Tilray shares fell as much as 15% Tuesday to a record low after the cannabis company missed fourth-quarter revenue and Ebitda estimates and recorded $181 million of writedowns and impairment charges.Several analysts cut their price targets on the stock, and some questioned whether Tilray will be able to meet its goal of reaching positive Ebitda by the fourth quarter of this year. Tamy Chen at BMO believes that won’t happen until 2022, in which case it will need to raise an additional $240 million of funding.Here’s what analysts are saying:Eight Capital, Graeme KreindlerKreindler cut his rating on Tilray …read more
Source:: Yahoo Finance
